Nowadays, three main treatments are available to lower plasma phenylalanine (Phe) levels in PKU, which is caused by mutations in the Phe hydroxylase (PAH) gene or by the deficiency of tetrahydrobiopterin (BH4) that acts as PAH cofactor (Blau et al., 2021). The gene discussed is PAH; the disease is phenylketonuria.